| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | TNDM | Common Stock | Options Exercise | $19,620 | +2,180 | +34% | $9.00 | 8,513 | 13 Sep 2021 | Direct | F1 |
| transaction | TNDM | Common Stock | Options Exercise | $1,545,000 | +30,000 | +352% | $51.50 | 38,513 | 13 Sep 2021 | Direct | F1 |
| transaction | TNDM | Common Stock | Sale | $1,772,100 | -15,000 | -39% | $118.14 | 23,513 | 13 Sep 2021 | Direct | F2, F3 |
| transaction | TNDM | Common Stock | Sale | $1,404,554 | -11,800 | -50% | $119.03 | 11,713 | 13 Sep 2021 | Direct | F2, F4 |
| transaction | TNDM | Common Stock | Sale | $262,319 | -2,180 | -19% | $120.33 | 9,533 | 13 Sep 2021 | Direct | F2, F5 |
| transaction | TNDM | Common Stock | Sale | $231,192 | -1,900 | -20% | $121.68 | 7,633 | 13 Sep 2021 | Direct | F2, F6 |
| transaction | TNDM | Common Stock | Sale | $159,172 | -1,300 | -17% | $122.44 | 6,333 | 13 Sep 2021 | Direct | F2, F7 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | TNDM | Stock Option | Options Exercise | $19,620 | +2,180 | $9.00 | 0 | 13 Sep 2021 | Common Stock | 2,180 | $9.00 | Direct | F8, F9 | |
| transaction | TNDM | Stock Option | Options Exercise | $1,545,000 | +30,000 | +300% | $51.50 | 40,000 | 13 Sep 2021 | Common Stock | 30,000 | $51.50 | Direct | F9, F10 |
| Id | Content |
|---|---|
| F1 | Represents shares of common stock received upon exercise of a stock option award. |
| F2 | The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2021. |
| F3 | The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $117.64 to $118.60. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. |
| F4 | The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $118.64 to $119.61. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. |
| F5 | The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $119.76 to $120.67. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. |
| F6 | The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $121.01 to $121.98. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. |
| F7 | The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $122.03 to $122.99. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. |
| F8 | The options vested as to twenty-five (25%) of the underlying shares on 5/17/2018, and the remaining shares vested in thirty-six (36) equal monthly installments thereafter, subject to the terms of Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the "2013 Plan"). |
| F9 | The expiration date for these options is 10 years from the date of grant. |
| F10 | The options vested as to twenty-five (25%) of the underlying shares on 2/15/2020, and the remaining shares shall vest in thirty-six (36) equal monthly installments thereafter, subject to (the "2013 Plan"). |